Bristol Myers and Pfizer Raise Revenue Forecasts Amid New Drug Replacement Strategy
PFE Pfizer Inc
$28.37 -0.11%
View chart & analysis → - 1Bristol Myers recorded an upward revision of approximately 5.9% for its 2026 revenue forecast based on its 2026 median.
- 2Pfizer announced an upward revision of approximately 0.8% for its 2026 revenue forecast based on its 2026 median.
- 3Bristol Myers projects an expected growth rate of 20% to 25% for Bristol Myers Eliquis in 2026.
So what's the key point?
Bristol Myers and Pfizer have raised their revenue forecasts for 2026. Bristol Myers increased its revenue forecast by 5.9% driven by the growth of Eliquis.
Source Trefis +2 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.